The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Patients with diabetes using a NovoPen Echo from one of the affected batches listed above should call Novo Nordisk at 1-855-419-8827 between 8 a.m. and 6 p.m. Eastern time to get a replacement ...